The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients
Open accessAbstract
BACKGROUND: Tumor recurrence, the chief reason for poor prognosis of glioma, is largely attributed to glioma stem cells (GSCs) and epithelial-mesenchymal transition (EMT). However, the mechanisms among them remain unknown. Here, we determined whether leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), known as a stem cell marker for colon cancer and gastric cancer, can serve as a novel GSC marker involved in EMT and a therapeutic target in glioma. METHODS: cells. Reported stem cell markers, EMT and the Wnt/β-catenin pathway were examined in stable LGR5 knockdown or overexpressed GSCs by Western Blot. The treatment experiment was performed in an intracranial orthotopic xenograft model by knockdown of LGR5 or by using the Wnt/β-catenin pathway inhibitor Wnt-C59. LGR5 expression was determined in 268 glioma specimens by immunohistochemistry. RESULTS: cells. The expression of SOX2, Nanog, CD133, CD44, CD24 and EpCAM was modulated by LGR5. Both LGR5 knockdown and Wnt-C59 reduced tumor invasion and migration and blocked EMT by inhibiting the Wnt/β-catenin pathway in vitro and suppressed the intracranial orthotopic xenograft growth and prolonged the survival of xenograft mice in vivo. Moreover, LGR5 was positively correlated with Ki67, N-cadherin and WHO grade and negatively correlated with IDH1. Glioma patients with high expression of LGR5 showed significantly poorer prognosis. CONCLUSIONS: LGR5 is a new functional GSC marker and prognostic indicator that can promote EMT by activating the Wnt/β-catenin pathway and would thus be a novel therapeutic target for glioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
Cited by
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Understanding and targeting resistance mechanisms in cancer
Lei, Z., Tian, Q., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. (2023) · MedComm · doi:10.1002/mco2.265 · Cited by 347
Wnt/β-catenin-driven EMT regulation in human cancers
Xue, W., Yang, L., Chen, C., Ashrafizadeh, M., Tian, Y., & Sun, R. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05099-7 · Cited by 321
Cao, L., Cui, Z., Zhang, D., Li, Y., Gao, X., Shang, R., Jiang, X.-D., Du, J., & Sun, X. (2024) · ACS Materials Letters · doi:10.1021/acsmaterialslett.4c01447 · Cited by 18
Metadata
- Authors
- Zhang, J., Cai, H., Sun, L., Zhan, P., Chen, M., Zhang, F., Ran, Y., & Wan, J.
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2018-09-12
- Volume
- 37
- Issue
- 1
- Pages
- 225-225
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- OpenAlex
- W2891968161
- Cited by
- 197
- References
- 1
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients. https://app.cochat.ai/papers/10.1186/s13046-018-0864-6
- The paper
- Zhang, J., Cai, H., Sun, L., Zhan, P., Chen, M., Zhang, F., Ran, Y., & Wan, J. (2018). LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-018-0864-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.